UPDATE 1-Abbott settles lawsuit related to its cholesterol drugs

Thu Nov 20, 2008 3:08pm EST
 
[-] Text [+]

(Recasts; adds details, stock movement)

Nov 20 (Reuters) - Abbott Laboratories Inc (ABT.N) said it settled a lawsuit related to the sale of its cholesterol-lowering formulations and would pay about $184 million to resolve the claims.

Abbott shares fell as much as 5 percent in afternoon trade.

In a regulatory filing, Abbott said it plans to record the settlement payments as a specified item in the fourth quarter.

The company said it had also settled some other previously-disclosed lawsuits related to the cholesterol-lowering fenofibrate formulations.

Abbott shares were trading down $2.52 at $52 on the New York Stock Exchange. They touched a low of $51.57 earlier. (Reporting by Esha Dey in Bangalore; Editing by Himani Sarkar)

 
Kenneth Griffin, Founder, President and CEO, Citadel Investment Group LLC, speaks during the "Financial Recovery: When and How?" panel at the 2009 Milken Institute Global Conference in Beverly Hills, California April 27, 2009. REUTERS/Phil McCarten
Citadel enters the fray

Kenneth Griffin's powerful hedge fund has waded into the case of Goldman Sachs' purloined computer code, suing three of its former employees for setting up Teza Technologies.  Full Article | Full Coverage 

Companies In This Article

Join the Reuters Consumer Insight Panel and help us get to know you better

Join the Reuters Consumer Insight Panel and help us get to know you better